{"id":584,"date":"2024-06-13T05:04:04","date_gmt":"2024-06-13T05:04:04","guid":{"rendered":"https:\/\/www.neolyspharma.ca\/nouvelles\/entente-sur-loctroi-dune-option-de-licence-exclusive-de-luniversite-laval-pour-lexploitation-commerciale-des-derives-aminosteroides\/"},"modified":"2026-08-01T18:00:46","modified_gmt":"2026-08-01T18:00:46","slug":"exclusive-licence-option-universite-laval-aminosteroid-derivatives","status":"publish","type":"nouvelles","link":"https:\/\/neolyspharma.ca\/en\/news\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\/","title":{"rendered":"Agreement on an exclusive licence option from Universit\u00e9 Laval for the commercial exploitation of aminosteroid derivatives."},"content":{"rendered":"

Neolys Pharma and Universit\u00e9 Laval have entered into an agreement granting the company an exclusive licence option for the commercial exploitation of aminosteroid derivatives.<\/p>\n

These compounds originate from work carried out at Universit\u00e9 Laval by the team of Dr. Donald Poirier, professor in the Department of Molecular Medicine and cofounder of Neolys Pharma. The agreement gives the company the access it needs to develop this family of molecules, including RM-581.<\/p>\n

The option forms the foundation of Neolys Pharma\u2019s intellectual property. It gives the company the right to obtain an exclusive licence on these compounds and secures the continuation of its preclinical development programme.<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":true},"categories":[],"class_list":["post-584","nouvelles","type-nouvelles","status-publish","hentry"],"acf":[],"yoast_head":"\nExclusive Licence Option from Universit\u00e9 Laval | Neolys Pharma<\/title>\n<meta name=\"description\" content=\"Neolys Pharma secures an exclusive licence option from Universit\u00e9 Laval for the commercial development of the aminosteroid derivatives.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neolyspharma.ca\/en\/news\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exclusive Licence Option from Universit\u00e9 Laval | Neolys Pharma\" \/>\n<meta property=\"og:description\" content=\"Neolys Pharma secures an exclusive licence option from Universit\u00e9 Laval for the commercial development of the aminosteroid derivatives.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neolyspharma.ca\/en\/news\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\/\" \/>\n<meta property=\"og:site_name\" content=\"Neolyspharma\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-01T18:00:46+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\\\/\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\\\/\",\"name\":\"Exclusive Licence Option from Universit\u00e9 Laval | Neolys Pharma\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#website\"},\"datePublished\":\"2024-06-13T05:04:04+00:00\",\"dateModified\":\"2026-08-01T18:00:46+00:00\",\"description\":\"Neolys Pharma secures an exclusive licence option from Universit\u00e9 Laval for the commercial development of the aminosteroid derivatives.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\\\/#breadcrumb\"},\"inLanguage\":\"en-CA\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/news\\\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agreement on an exclusive licence option from Universit\u00e9 Laval for the commercial exploitation of aminosteroid derivatives.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\",\"name\":\"Neolys Pharma\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#organization\"},\"inLanguage\":\"en-CA\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#organization\",\"name\":\"Neolys Pharma inc.\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neolyspharma.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/neolys-logo.png\",\"contentUrl\":\"https:\\\/\\\/neolyspharma.ca\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/neolys-logo.png\",\"width\":512,\"height\":242,\"caption\":\"Neolys Pharma inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neolyspharma.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neolys-pharma\"],\"legalName\":\"Neolys Pharma inc.\",\"telephone\":\"+1-418-931-2195\",\"email\":\"info@neolyspharma.ca\",\"description\":\"A biopharmaceutical company based in Qu\u00e9bec City, Neolys Pharma develops RM-581, a synthetic aminosteroid targeting poor-prognosis cancers.\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exclusive Licence Option from Universit\u00e9 Laval | Neolys Pharma","description":"Neolys Pharma secures an exclusive licence option from Universit\u00e9 Laval for the commercial development of the aminosteroid derivatives.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neolyspharma.ca\/en\/news\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\/","og_locale":"en_US","og_type":"article","og_title":"Exclusive Licence Option from Universit\u00e9 Laval | Neolys Pharma","og_description":"Neolys Pharma secures an exclusive licence option from Universit\u00e9 Laval for the commercial development of the aminosteroid derivatives.","og_url":"https:\/\/neolyspharma.ca\/en\/news\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\/","og_site_name":"Neolyspharma","article_modified_time":"2026-08-01T18:00:46+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/neolyspharma.ca\/en\/news\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\/","url":"https:\/\/neolyspharma.ca\/en\/news\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\/","name":"Exclusive Licence Option from Universit\u00e9 Laval | Neolys Pharma","isPartOf":{"@id":"https:\/\/neolyspharma.ca\/en\/#website"},"datePublished":"2024-06-13T05:04:04+00:00","dateModified":"2026-08-01T18:00:46+00:00","description":"Neolys Pharma secures an exclusive licence option from Universit\u00e9 Laval for the commercial development of the aminosteroid derivatives.","breadcrumb":{"@id":"https:\/\/neolyspharma.ca\/en\/news\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\/#breadcrumb"},"inLanguage":"en-CA","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neolyspharma.ca\/en\/news\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/neolyspharma.ca\/en\/news\/exclusive-licence-option-universite-laval-aminosteroid-derivatives\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neolyspharma.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Agreement on an exclusive licence option from Universit\u00e9 Laval for the commercial exploitation of aminosteroid derivatives."}]},{"@type":"WebSite","@id":"https:\/\/neolyspharma.ca\/en\/#website","url":"https:\/\/neolyspharma.ca\/en\/","name":"Neolys Pharma","description":"","publisher":{"@id":"https:\/\/neolyspharma.ca\/en\/#organization"},"inLanguage":"en-CA"},{"@type":"Organization","@id":"https:\/\/neolyspharma.ca\/en\/#organization","name":"Neolys Pharma inc.","url":"https:\/\/neolyspharma.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/neolyspharma.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/neolyspharma.ca\/wp-content\/uploads\/2026\/08\/neolys-logo.png","contentUrl":"https:\/\/neolyspharma.ca\/wp-content\/uploads\/2026\/08\/neolys-logo.png","width":512,"height":242,"caption":"Neolys Pharma inc."},"image":{"@id":"https:\/\/neolyspharma.ca\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neolys-pharma"],"legalName":"Neolys Pharma inc.","telephone":"+1-418-931-2195","email":"info@neolyspharma.ca","description":"A biopharmaceutical company based in Qu\u00e9bec City, Neolys Pharma develops RM-581, a synthetic aminosteroid targeting poor-prognosis cancers."}]}},"_links":{"self":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/nouvelles\/584","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/nouvelles"}],"about":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/types\/nouvelles"}],"wp:attachment":[{"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/media?parent=584"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/neolyspharma.ca\/en\/wp-json\/wp\/v2\/categories?post=584"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}